Combination therapy for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new combination of two targeted therapy drugs (avutometinib and defactinib) plus standard chemotherapy (mFOLFIRINOX) given before any other treatment for pancreatic cancer. The goal is to see if this combination can shrink tumors more effectively and improve outcomes for patients with advanced pancreatic cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have pancreatic cancer that is either metastatic (spread to other organs) or borderline resectable/locally advanced (not removable by surgery right now)
- You must not have had any prior treatment for your pancreatic cancer
- You must be able to take oral pills and be willing to follow the treatment plan
- You must be in generally good health with a performance status of 0 or 1 (able to do daily activities without major limitations)
- You must have adequate liver, kidney, and blood cell function, and no serious heart rhythm problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This study tests a combination of drugs (an investigational immunotherapy, a targeted therapy, and chemotherapy) as a second-line treatment for people with advanced pancreatic cancer. The goal is to see if this combination can help slow down or stop the cancer when the first treatment no longer works.
This trial tests a new combination of three drugs for a type of pancreatic cancer that cannot be removed by surgery but has not spread to other parts of the body. The goal is to see if this combination can shrink or slow the cancer better than the current standard therapy.
This trial tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) for people with advanced lung adenocarcinoma that has a specific gene mutation (LKB1) and has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this new combination can shrink tumors or slow cancer growth.
This trial tests a new drug, pegcetacoplan, combined with a standard chemotherapy regimen called modified FOLFIRINOX, for people with pancreatic cancer that has spread to other parts of the body. The goal is to see if the combination helps control the cancer better than chemotherapy alone.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.